







(A)**(GSE73403)****(B)****(GSE74777)****(C)****(GSE157009)****(D)****(GSE157010)****(E)****(GSE157011)****(F)****(GSE67061)**

Supplementary Figure 3. Verification of the six-gene LAPS risk model as an independent prognostic factor and distribution of the low- and high-risk groups in the six validation cohorts. Multivariate regression analyses of clinical parameters. **(A)** GSE73403, **(B)**GSE74777, **(C)** GSE157009, **(D)** GSE157010, **(E)** GSE157011, and **(F)** GSE67061) in high- and low-risk groups.

Tumor stage, TNM stage, gender, patient age, and smoking are shown as patient annotations.